Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAISE-MR: Sacubitril-Valsartan in HFpEF with Secondary Mitral Regurgitation
2023-506634-70-00Phase 4Completed
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) and Mitral regurgitation (MR), sponsored by Ziekenhuis Oost-Limburg. Primary endpoint: Change in mPAP/CO slope. Started Oct 2023; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)Mitral regurgitation (MR)
Beyond the preview
Go deeper on 2023-506634-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506634-70-00.